(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-10)
Expected move: +/- 14.10%
@ $1.280
发出时间: 14 Feb 2024 @ 22:35
回报率: -7.03%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 11.20 %
Live Chart Being Loaded With Signals
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom...
Stats | |
---|---|
今日成交量 | 849 990 |
平均成交量 | 1.59M |
市值 | 270.33M |
EPS | $0 ( 2024-03-04 ) |
下一个收益日期 | ( $-0.160 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.20 |
ATR14 | $0.00600 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Ecor1 Capital, Llc | Buy | 0 | Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 5 088 864 | Option to purchase Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 1 130 832 | Option to purchase Ordinary Shares |
2024-01-17 | Rawcliffe Adrian | Sell | 30 080 | American Depositary Shares representing Ordinary Shares |
2024-01-16 | Rawcliffe Adrian | Sell | 9 304 | American Depositary Shares representing Ordinary Shares |
INSIDER POWER |
---|
96.15 |
Last 96 transactions |
Buy: 71 750 188 | Sell: 1 254 319 |
音量 相关性
Adaptimmune Therapeutics 相关性 - 货币/商品
Adaptimmune Therapeutics 财务报表
Annual | 2023 |
营收: | $60.51M |
毛利润: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2023 |
营收: | $60.51M |
毛利润: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2022 |
营收: | $27.15M |
毛利润: | $-100.58M (-370.48 %) |
EPS: | $-1.030 |
FY | 2021 |
营收: | $6.15M |
毛利润: | $6.15M (100.00 %) |
EPS: | $-1.020 |
Financial Reports:
No articles found.
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。